Novo Nordisk Sees 49.9% Stake Sale and Debuts Daily Oral Wegovy Pill
Commonwealth Equity Services sold 49.9% of its Novo Nordisk stake, disposing of 237,049 shares to leave 237,978 shares valued at $13.2 million at the end of Q3. Novo Nordisk launched its first once-daily oral Wegovy weight-loss pill, as announced by EVP Dave Moore on CNBC’s The Claman Countdown, expanding its GLP-1 portfolio beyond injectables.
1. Major Stake Reduction by Commonwealth Equity Services LLC
Commonwealth Equity Services LLC cut its position in Novo Nordisk A/S by 49.9% during the third quarter, selling 237,049 shares and ending the period with 237,978 shares. At the close of the reporting period, the remaining stake was valued at $13.21 million, marking one of the most significant single-manager divestitures in the company’s recent filings.
2. Other Institutional Movements Show Varied Strategies
Several smaller asset managers adjusted their exposure to Novo Nordisk A/S. True Wealth Design LLC increased its holding by 209.8%, adding 300 shares to reach 443 shares worth approximately $25,000. NewSquare Capital LLC grew its stake by 174.1%, acquiring 282 shares to total 444 shares valued at $31,000. Mid American Wealth Advisory Group Inc. initiated a new position worth about $37,000, while Maseco LLP established a position of $39,000. Copeland Capital Management LLC boosted its position by 47.3%, purchasing 186 additional shares to reach 579 shares valued at $40,000. Hedge funds and other institutions collectively own 11.54% of the company’s stock.
3. Q3 Earnings Exceed Expectations with Robust Profitability
In its latest quarterly report, Novo Nordisk A/S delivered earnings per share of $1.02, surpassing analyst estimates by $0.25, and generated revenue of $11.79 billion, narrowly missing consensus by $0.19 billion. The company achieved a return on equity of 73.50% and a net margin of 32.76%, underscoring strong operational efficiency. Management reaffirmed its full-year EPS guidance of 3.84, reflecting confidence in sustained product demand and pricing power across its diabetes and obesity care portfolio.
4. Divergent Analyst Ratings Reflect Balanced Outlook
Brokerage assessments of Novo Nordisk A/S remain mixed. One firm maintains a strong buy recommendation, seven advocate a buy, eleven issue hold ratings and four recommend selling. Recent actions include a downgrade to underperform by Jefferies Financial Group and a sell rating reaffirmation by Weiss Ratings, counterbalanced by a buy upgrade from Berenberg Bank. The consensus rating stands at Hold, indicating measured investor sentiment despite the company’s market leadership in metabolic health.